An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen

Trial Profile

An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Dolutegravir/rilpivirine (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 12 Dec 2017 Results assessing changes at Week 48 in BMD after switching from a three-drug regimen containing tenofovir disoproxil fumarate to the NRTI-sparing dolutegravir+rilpivirine regimen, were published in the AIDS.
    • 26 Jul 2017 Primary endpoint (Percentage change from baseline at Week 48 in total hip BMD as assessed by areal density in gram per centimeter square (g/cm^2)) has been met, as per the results presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top